Bio Platforms

EXECUTIVE INTERVIEW – Viral Gene: Protein-Targeting Cancer Vaccine Could Boost Survival Rates

Harry A. Arena, MBA, President & CEO of TDT, Chris Kim, President & General Counsel, Viral Gene, Inc., and Dr. Scott Waldman, Professor & Chair of Sidney Kimmel Medical College’s Department of Pharmacology & Experimental Therapeutics at Thomas Jefferson University, discuss the unique characteristics of the vaccine, the patients who will benefit the most, and how a research team captured the attention of investors.

PLATFORM TECHNOLOGY – ​​The 3DNA® Platform for Targeted Drug Delivery

Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.

EXCLUSIVE ONLINE CONTENT